![](https://news.europawire.eu/wp-content/uploads/2020/06/roche-logo-144x144.jpg)
Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen approved for the treatment of unresectable or metastatic hepatocellular carcinoma Tecentriq combination improved overall survival and progression-free survival compared to the previous standard of care Application approved … Read the full press release